Cerenome, Inc. CNSY
0.68 USD +0.11 (+19.01%)
At closeNov 10, 2026, 7:56 PM EST
0.66 -0.02 -2.67%
After hours · Nov 10, 7:56 PM ET
0.4287 Day range 0.6899
0.4287 52-week range 19.00
- YTD
- -94.68%
- 1 year
- -95.16%
- Market cap
- 5.15M
- EPS (ttm)
- -3.36
- YTD return
- -94.68%
- 1-year return
- -95.16%
- Volume
- 1.16M
- Avg volume
- 635.50K
- Open
- 0.5589
- Previous close
- 0.5698
- Day's range
- 0.4287 – 0.6899
- 52-week range
- 0.4287 – 19.00
5D -1.0192 (-59.95%)
Financials — quick view
CNSY Revenue — quarterly 411.00K
CNSY Net income — quarterly -9.01M
CNSY EPS — quarterly -1.31
News
Cerenome Appoints Director Ron Andrews as Chief Business Officer 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
CNSide Diagnostics Inks National In-Network Laboratory Ancillary Provider With Aetna Health Plans 
Cerenome Secures National In-Network Agreement with Aetna for CNSide® - 12 Health Care Stocks Moving In Tuesday's Intraday Session
Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma 
Cerenome To Report Poster Presentation Of Interim Data From Its Current ReSPECT-LMM Multidose Trial Of REYOBIQ At 31st Annual Meeting And Education Day 
Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases 
New Strong Sell Stocks for October 22nd - Cerenome Presents New Preclinical Data At 16th Biennial Rivkin Ovarian Cancer Research Symposium Regarding Immunomodulatory Properties Of REYOBIQ
Your note
Sign in to keep a note on CNSY — it syncs with the Stock Master app.